Hetero has received the Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) for restricted use of the generic version of tocilizumab in India. 

This authorization will allow medical practitioners to use the generic drug for the treatment of COVID-19 in hospitalized adult patients who are being given systemic corticosteroids and need supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Hetero’s tocilizumab will be marketed by Hetero Healthcare in India. Hetero’s biologics arm ‘Hetero Biopharma’ will manufacture the drug at its biologics facility in Hyderabad. This drug is the biosimilar version of Roche’s Actemra/RoActemra®, and will be available from the end of this month… (ET Healthworld, September 7, 2021)